Pavé S1 (CBD): A Comprehensive Strain Guide

History and Market Context

Pavé S1 (CBD) sits at the intersection of modern dessert-gas cannabis trends and the renewed demand for functional, low-intoxication flower. Pavé itself rose to prominence in the early 2020s as breeders and tastemakers pushed “icy,” jewelry-inspired bag appeal paired with dense, pastry-like aromatics and a menthol-tinged finish. As CBD-forward products rapidly diversified post-2018 Farm Bill, breeders began stabilizing CBD chemotypes that still carried contemporary terpene signatures consumers love.

By 2022, U.S. shoppers were primed to explore terpene diversity—industry observers noted there are more terpene combinations than could be sampled in a lifetime, and to “leave room for butter and dough aroma amid funk, floral” influences. Pavé’s minty-fresh-meets-bakery character slotted neatly into that trend, while CBD-oriented selections appealed to wellness-minded buyers who wanted the flavor story without hard-hitting intoxication. In dispensary data from several mature markets, CBD-labeled flowers and prerolls maintained steady year-over-year sales even as total category growth slowed, indicating a sustained niche for balanced and CBD-dominant offerings.

The S1 designation signals an intentional effort to self-stabilize a chosen phenotype so that growers can reproduce aroma, structure, and chemotype more reliably. For cultivators, this reduces the variability commonly seen in polyhybrid seeds and shortens the time to a predictable, market-ready product. For consumers, Pavé S1 (CBD) represents a strain that tastes current, looks premium, and performs comfortably for daytime or high-function use cases.

While Pavé’s original, high-THC versions captured attention for thick frost and menthol-OG swagger, the CBD-directed S1 offers that experience in a more approachable lane. The result is a cultivar that can headline a terpene-forward CBD shelf, anchor 1:1 product lines, or serve as a flavorful mixer for low-THC blends. In short, Pavé S1 (CBD) reflects where connoisseur flavor and pragmatic cannabinoid needs meet in 2025’s market.

Genetic Lineage and Breeding Pathway

Pavé is widely associated with modern OG/Kush-influenced lines and a menthol-forward parentage, frequently reported to involve The Menthol and an OG-family selection such as Paris OG. Exact recipes can be proprietary, but the reputation is consistent: dense, resinous flowers, a cool mint lift, and doughy-gassy undertones. Those traits provide a strong backbone for breeders aiming to capture a dessert-meets-fresh profile in a stabilized seed line.

The S1 suffix indicates a selfed line, created by reversing a female Pavé selection and pollinating it with itself to produce seeds. Selfing increases homozygosity, which can lock in desirable traits like bud structure, frost, and aroma, while exposing recessive weaknesses that careful selection can weed out. With CBD added to the equation, breeders either selected a naturally balanced chemotype from Pavé progeny or first introduced a CBD-dominant donor, then selected and selfed a CBD-forward Pavé-leaning phenotype.

From a biochemical standpoint, a cultivars’ THC:CBD ratio is strongly governed by the plant’s alleles at the cannabinoid synthase loci (THCAS vs CBDAS). Type I plants are THC-dominant (THCAS active), Type II are balanced (both enzymes present), and Type III are CBD-dominant (CBDAS active). A CBD-forward Pavé S1 likely follows Type II or Type III chemotype inheritance patterns, which can be tested via PCR markers or confirmed in finished flower COAs.

In practical terms, Pavé S1 (CBD) should present notably less intoxicating power than classic Pavé while retaining its cold, creamy-funky terp signature. Growers selecting keeper moms will aim for vigorous stacking, above-average trichome coverage, and a terp split that emphasizes buttered dough, mint, and floral-gas. Across multiple seed packs, expect some variation in chemotype expression, but S1 work typically narrows the range enough that 2–3 keeper candidates emerge quickly in a 10–20 plant hunt.

Appearance and Bag Appeal

Visually, Pavé S1 (CBD) stays true to the “pavé diamonds” inspiration: buds appear heavily dusted in trichomes, giving them a bright, icy sheen under direct light. Calyxes tend to stack tightly, producing golf-ball to cone-shaped flowers with a high calyx-to-leaf ratio that trims cleanly. Hues can range from lime to deeper olive green, sometimes accented by lavender streaks at cooler night temperatures.

Pistils usually present as slender and copper-orange, weaving through the frost without dominating the overall color palette. When grown under optimal PPFD and balanced nutrition, the trichome heads mature uniformly, which is crucial for consistent CBD potency and a terp-rich cure. Expect resin rails on bracts and sugar leaves, the kind that leave sticky fingerprints on scissors during trim.

Bag appeal is elevated by the contrast between glittering resin and doughy, mint-forward aromatics that escape the jar on first crack. A well-cured Pavé S1 (CBD) nug often feels dense yet springy, suggesting proper dry-back and intracellular water balance. Many buyers judge with their nose and eyes first—this strain’s visual and aromatic cues check those boxes decisively.

Under magnification, trichome heads typically sit in the 70–120 μm diameter range, which is excellent for solventless extraction yields. While absolute yields will vary by cut and process, a resin-rich CBD cultivar like this can produce competitive bubble hash and rosin, especially when harvested at peak cloudiness. The end product often appears pale to light gold, reflecting both high resin purity and the cultivar’s bright terpene profile.

Aroma: Buttered Dough Meets Funk and Floral

Aroma is where Pavé S1 (CBD) earns its place among modern connoisseur cultivars. On dry pull, expect a forward note of buttered dough—think warm brioche—wrapped around a mint-cool lift and an undercurrent of floral-gassy funk. This layered bouquet aligns with the broader trend that encouraged consumers to “leave room for butter and dough aroma amid funk, floral,” highlighting how dessert-esque notes can coexist with classic cannabis funk.

Once ground, volatile esters and terpene alcohols open up, pushing sweet pastry, hints of vanilla, and a fresh, menthol-adjacent breeze. The funk component likely draws from caryophyllene-humulene synergy, while the minty lift can come from terpenes like eucalyptol and borneol, or minor oxygenated compounds that read as “cool.” Skilled curing accentuates the bakery side without flattening the green, resinous core.

Terpene totals in premium flower commonly range from 1.5% to 3.5% by weight, and Pavé S1 (CBD) often sits comfortably in that band when grown carefully. Higher terpene content not only intensifies the nose but also correlates with perceived freshness and mouth-coating flavor. Beware of over-drying; terpene loss accelerates above 0.75 kPa VPD during late dry, which can mute the buttery top notes.

Minor sulfur-containing volatiles can contribute to the “gas” twist, even at parts-per-billion levels. Research in 2021 identified volatile sulfur compounds (VSCs) as key to pungent “skunk/gas” character, which explains how a doughy-mint profile can still feel assertive. In short: Pavé S1 (CBD) is not a faint, purely floral CBD—you get a full-spectrum, contemporary nose with real presence.

Flavor and Mouthfeel Across Consumption Methods

On the palate, Pavé S1 (CBD) tends to track the nose closely: lightly sweet pastry at the front, a clean mint-cool through the mid, and a peppery-gassy exhale. Vaporizing at 170–190°C (338–374°F) emphasizes confectionery esters and the floral elements, delivering a silky texture and lingering sweetness. Combustion pushes the pepper and gas while preserving the minty lift, especially in glassware with good airflow.

In joints, the first third often tastes like buttery cookie dough before transitioning to crisp herb and a subtle floral bitterness that keeps it from cloying. In a vaporizer, discrete temperature stepping reveals layers—start low for bakery notes, then increase 5–10°C to unlock the mint and spice. The finish is clean, with minimal throat scratch when properly cured and flushed.

Edible infusions made from Pavé S1 (CBD) extracts carry over a surprising amount of the dessert profile if terpene-friendly extraction is used. Lipid infusions at lower decarboxylation temperatures (e.g., 105–110°C for 45–60 minutes) can preserve aromatic complexity better than aggressive heating. For tinctures or sublinguals, ethanol-based extracts can deliver clear mint-floral top notes, though some peppery caryophyllene may become more pronounced.

Mouthfeel matters in repeat use, and Pavé S1 (CBD) offers a notably plush, non-astringent experience when grown and cured correctly. That tactile softness complements its mellow effect profile, making it a popular choice for daytime sipping sessions. Overall, the flavor follows modern dessert-gas expectations without the heaviness some find in diesel-dominant cultivars.

Cannabinoid Profile and Ratios

Because Pavé S1 (CBD) refers to a CBD-forward, selfed line of a modern terpene cultivar, potency can vary by cut and cultivation. In practice, CBD-dominant flowers in legal markets commonly test at 8–16% CBD by weight, with THC ranging from trace to about 3–6% if the cultivar expresses a balanced (Type II) chemotype. For strictly CBD-dominant (Type III) cuts targeting compliance hemp thresholds, THC is usually at or below 0.3% delta-9 by dry weight when harvested at the right time.

Many Pavé S1 (CBD) selections land in the balanced-to-CBD-leaning window—think 1:1 up to 10:1 CBD:THC ratios—depending on breeder selection. Consumers often report that a 2:1 to 5:1 CBD:THC ratio hits a sweet spot for calm without impairment, aligning with observational data from wellness programs. Minor cannabinoids such as CBC and CBG often appear in the 0.2–1.5% combined range, contributing subtly to the entourage effect.

Decarboxylation converts CBDA and THCA into their active forms; typical flower shows a majority of cannabinoids in acid form prior to heating. In lab results, “total CBD” usually accounts for CBDA x 0.877 plus CBD, and similarly for THC. Accurate COAs are essential, as decarb efficiency, moisture content, and lab methodology can shift reported totals by several percentage points.

If the cultivar is being grown for hemp compliance, careful pre-harvest testing is critical. THC often rises late in flower even in CBD-dominant plants, so harvest timing becomes a balancing act between CBD maturation and THC thresholds. For non-hemp, dispensary-bound production, the focus is on maximizing total cannabinoids and terpene retention rather than absolute THC minimization.

Terpene Profile and Volatile Compounds

The expected terpene profile for Pavé S1 (CBD) prioritizes caryophyllene, limonene, and myrcene as core drivers, with supporting roles from linalool, humulene, and pinene isomers. Caryophyllene can account for 0.3–0.9% by weight in terp-rich phenotypes, lending pepper-spice warmth and interacting with CB2 receptors according to pharmacological studies. Limonene in the 0.2–0.7% range contributes bright citrus lift that reads as “fresh” beside the buttery base.

Myrcene (0.2–0.8%) provides the soft, musky backdrop that anchors sweet dough aromatics, while linalool (0.05–0.3%) introduces lavender-like floral facets. Humulene and alpha- and beta-pinene collectively add herbal bitterness and piney freshness that keeps the profile from skewing too sweet. In total, terpene content often lands between 1.5% and 3.0% in well-grown, CBD-forward cuts of modern dessert-gas cultivars.

Beyond major terpenes, oxygenated monoterpenes such as eucalyptol (1,8-cineole) and borneol may explain the cooling effect reported by many Pavé fans. Trace esters and lactones can evoke buttery and creamy associations, even when present at very low concentrations. Meanwhile, volatile sulfur compounds, measured in parts-per-billion, are known to deliver the “gas” edge despite their tiny abundance.

Environmental control strongly impacts terp expression. Studies and commercial experience show higher nighttime temps can suppress certain floral esters, while gentle day/night swings encourage balanced monoterpene synthesis. Maintaining moderate VPD and avoiding late-flower heat spikes helps preserve sensitive volatiles that define Pavé S1 (CBD)’s pastry-mint signature.

Experiential Effects and Use Patterns

Pavé S1 (CBD) is crafted for clarity and calm rather than intense intoxication. Most users describe a clear-headed, body-light relaxation with minimal impairment, consistent with CBD-dominant or balanced chemotypes. The mint-cool sensory cue often matches a subtle psychological “refresh,” while the doughy sweetness imparts a cozy, familiar undertone.

Inhalation typically produces noticeable effects within 1–3 minutes, peaking at around 10–20 minutes, and tapering over 2–4 hours depending on dose. Edible forms show onset at 45–120 minutes, with duration commonly stretching 4–8 hours. Sublingual tinctures fall in between, often reaching effect in 15–45 minutes.

Because CBD modulates CB1 activity indirectly and can temper THC’s acute effects, balanced Pavé S1 (CBD) phenotypes tend to avoid anxiety spikes even for sensitive users. Many report heightened comfort in social and creative settings with little distraction or short-term memory disruption. For daytime use, microdosing via one or two vaporizer pulls or a small joint “taster” is often sufficient.

At higher doses, the profile leans toward full-body ease and gentle muscle softening without couchlock for most people. The absence of edgy stimulation makes it suitable for winding down after work or for low-stakes focus tasks. As always, individual responses vary; tolerance, set, and setting play meaningful roles.

Potential Medical Applications and Evidence

CBD’s most robust, regulatory-grade evidence lies in treatment-resistant epilepsy; purified CBD has shown median seizure reductions in the 36–50% range in Dravet and Lennox–Gastaut syndromes. While whole-plant CBD flower is not equivalent to prescription isolate, many patients value inhaled or sublingual CBD for rapid onset during prodromal phases or breakthrough discomfort. For Pavé S1 (CBD), the added appeal is adherence—patients are more likely to use a product consistently when it tastes and smells good.

For anxiety, small human studies suggest acute doses around 300 mg oral CBD can reduce performance anxiety in a simulated public speaking test. Real-world medical cannabis registries also report improvements in anxiety and sleep metrics among CBD-dominant users, although results vary and placebo effects are nontrivial. Balanced THC:CBD preparations sometimes outperform CBD alone for pain and sleep in observational cohorts.

Chronic pain data for cannabinoids is mixed but generally supportive for a subset of patients. Meta-analyses indicate modest-to-moderate reductions in pain intensity, with better responses reported in neuropathic pain and spasticity. CBD’s anti-inflammatory and anti-hyperalgesic properties may contribute, and caryophyllene (abundant in many Pavé cuts) is a CB2 agonist, potentially adding peripheral benefit.

Patients with muscle tension, stress-related headaches, or post-exercise soreness often favor CBD-dominant flowers for daytime relief without intoxication. Inhalation allows dose titration: two puffs, wait five minutes, reassess. As with all medical use, clinicians advise starting low and proceeding slowly, particularly when other sedatives or CYP450-metabolized medications are involved.

It’s important to emphasize that individual biochemistry, comorbidities, and product variability can outweigh strain-level expectations. Patients should request current certificates of analysis (COAs) to confirm CBD:THC ratios and terpene content, and coordinate with healthcare providers for integrated care. Pavé S1 (CBD) provides an appeali